As GLP-1 brands become crowded and chemically similar, pharma companies need a stronger way to build doctor preference, support patient continuation, and protect brand value beyond price.
As GLP-1 brands become crowded and chemically similar, pharma companies need a stronger way to build doctor preference, support patient continuation, and protect brand value beyond price.